Review infection risk and the withdrawal plan.
Prednisone can suppress immunity and adrenal function. Do not change or stop prolonged treatment without a clinician-directed plan. Report infection exposure, severe mood changes, black stools or marked weakness; illness/surgery may require stress-dose coverage.
Warnings and precautionsIndications
Broad label indications require a disease-specific treatment decision.
Labeled oral indications
Selected immediate-release labeling covers endocrine conditions, rheumatic/connective-tissue disease, severe allergic/skin/ocular inflammatory disorders, selected pulmonary/hematologic disorders, neoplastic palliation, nephrotic syndrome and inflammatory bowel disease. Examples include RA/lupus flares, severe asthma/allergy unresponsive to usual treatment, and ulcerative colitis/Crohn-type regional enteritis. Selected infections require appropriate anti-infective co-treatment. Hydrocortisone/cortisone are preferred for adrenal replacement; mineralocorticoids may also be needed.
Delayed-release scope and clinical selection
Delayed-release labeling also includes selected transplant-rejection and additional disease indications. Treat its indication list as regulatory wording rather than a recommendation to use steroids for every listed condition. Choice, duration and combination treatment depend on contemporary disease guidance; this profile does not supply disease-specific flare protocols. Delayed release is not an emergency rescue substitute.
Dosage and administration
Dose depends on the diagnosis, severity, response and exposure duration.
Individualized oral dosing
Both selected full labels describe initial doses often 5–60 mg/day; less severe illness may need less, and some conditions require more. Continue/adjust until response, then reduce to the lowest effective maintenance dose. Pediatric dosing follows disease severity and response rather than a single age/weight ratio. No universal pediatric mg/kg regimen or maximum is inferred.
| Formulation | Administration |
|---|---|
| Immediate-release tablet | Take with food or milk to reduce stomach irritation. For a prescribed single daily dose, selected label favors morning before 9 am; divided schedules depend on the regimen. |
| Delayed-release prednisone / Rayos | Take with food; swallow intact, without breaking/dividing/chewing. Release starts ~4 hours after intake; choose timing for the disease and formulation. Do not automatically apply IR morning timing. |
| IR → delayed release | Prescriber uses an equivalent glucocorticoid dose based on relative potency and adapts timing; prednisone/prednisolone 5 mg correspond to methylprednisolone 4 mg or hydrocortisone 20 mg for the label’s oral/IV comparison. |
Tapering and adrenal recovery
The 2024 ESE/Endocrine Society guideline generally suggests no adrenal taper/testing for courses <3–4 weeks. Longer treatment should be tapered only when the disease is controlled and steroids are no longer needed; reduce toward physiologic prednisone-equivalent 4–6 mg/day, then individualize clinical monitoring or morning cortisol testing. Disease relapse and withdrawal symptoms may alter the plan. Labels caution against abrupt withdrawal after prolonged therapy; no fixed taper fits everyone.
Renal, hepatic and stress considerations
No fixed eGFR/hepatic dose formula is provided. Renal insufficiency, hypertension and HF increase concerns from salt/water retention and potassium loss. Cirrhosis can enhance corticosteroid effects through reduced metabolism; thyroid status also affects clearance. Acute stress may require a rapidly acting steroid or supplemental coverage rather than relying on delayed-release timing.
Safety
Immunosuppression, metabolic effects and adrenal suppression affect all systemic regimens.
Warnings and precautions
- Can cause HPA suppression, Cushing features and hyperglycemia; adrenal insufficiency may persist after withdrawal. Severe weakness, hypotension or vomiting after reduction/illness needs urgent assessment.
- Infections may worsen, reactivate or be masked. Screen for hepatitis B before immunosuppressive/prolonged therapy; assess TB, Strongyloides or amebiasis risks as relevant. Varicella/measles exposure in a nonimmune patient needs prompt prophylaxis review.
- Avoid systemic fungal infection except when required for a specific drug reaction under specialist care. Avoid live vaccines at immunosuppressive doses; inactivated responses may be reduced.
- Monitor BP/fluid retention and potassium, especially with HF/renal disease; use great caution after recent MI. GI ulceration/perforation can occur with muted signs.
- Mood changes, insomnia, mania, severe depression or psychosis, osteoporosis/fractures, myopathy, impaired healing and reduced child growth may occur. Cataracts/glaucoma and ocular infection require attention; avoid active ocular herpes simplex.
- Systemic sclerosis requires particular caution: supplemental primary prednisolone labeling warns of potentially fatal scleroderma renal crisis. Monitor BP/creatinine; sudden hypertension or reduced urine needs urgent specialist assessment.
Contraindications
The selected immediate-release label formally contraindicates systemic fungal infection and ingredient hypersensitivity. The selected delayed-release section 4 lists hypersensitivity; fungal infection is an avoidance warning in section 5.2. Live vaccines are contraindicated at immunosuppressive corticosteroid doses. Distinguish the exact product’s section-4 wording from precautions.
Boxed warning status
No boxed warning appears in the selected prednisone tablet labels. Lack of a box does not reduce the significance of adrenal crisis, infection, bone loss or other systemic risks.
Adverse reactions and excessive exposure
Reported effects include appetite/weight gain, edema, increased BP/glucose, insomnia/mood changes, dyspepsia, acne/bruising and poor wound healing. Prolonged therapy can cause adrenal suppression, osteoporosis/osteonecrosis, cataracts/glaucoma and serious infections. Rates vary with dose/duration and cannot be inferred from spontaneous reports. Suspected overdose needs prompt medical/toxicology guidance; do not induce vomiting at home or abruptly stop chronic treatment to correct excess exposure.
Drug interactions
Interactions change exposure, glucose, potassium, bleeding and infection risks.
Clinically relevant interactions
| Combination | Action |
|---|---|
| CYP3A4 inhibitors (azole antifungals, ritonavir, macrolides) / inducers (rifampin, phenytoin, carbamazepine) | Exposure can rise/fall; review response, systemic toxicity and adjustment. |
| NSAIDs / aspirin | GI adverse risk rises; aspirin clearance can change and withdrawal may increase salicylate levels. |
| Warfarin | Anticoagulant response may increase or decrease; monitor INR/coagulation more frequently. |
| Antidiabetic agents | Steroid glucose elevation may require treatment adjustment and more checks. |
| Potassium-depleting diuretics / amphotericin B; digoxin | Monitor potassium; hypokalemia increases arrhythmia risk with digoxin. |
| Cyclosporine | Both drugs’ effects may rise; seizures have been reported. |
| Anticholinesterases in myasthenia gravis | Severe weakness risk; specialist supervision and respiratory-support planning. |
| Fluoroquinolones | Tendon rupture risk increases, especially in older adults. |
| Bupropion / thalidomide | Review seizure risk / serious skin reaction risk respectively. |
| Vaccines / skin testing | Avoid live vaccine at immunosuppressive doses; immune/test responses may be blunted. |
Use in specific populations
Children, older adults and pregnancy require exposure-specific assessment.
Pregnancy and lactation
Human corticosteroid pregnancy studies show a small, inconsistent orofacial-cleft association; underlying disease can confound growth/birth-weight outcomes. Weigh maternal benefit and fetal risk and observe infants after substantial maternal doses for adrenal suppression. Prednisolone enters milk; modern delayed-release labeling estimates infant exposure <1% of maternal daily dose with no reported infant adverse effects in cited reports, but prolonged high doses may affect growth/adrenal function. Balance breastfeeding and maternal treatment individually.
Pediatric and geriatric considerations
Pediatric evidence includes nephrotic syndrome >2 years and aggressive leukemia/lymphoma >1 month, with other indications supported partly by adult evidence; these are evidence descriptions, not a universal minimum age. Individualize treatment and monitor height/growth, BP, weight and infection. Older adults need cautious dosing and surveillance for bone loss, diabetes, hypertension, edema and infection.
Hepatic and renal impairment
Selected delayed-release PK studies have not evaluated renal/hepatic impairment. IR labeling notes increased effects in cirrhosis and cautions in renal insufficiency/HF. Individualize and monitor metabolic/fluid effects rather than assuming a numeric adjustment or absence of risk.
Clinical pharmacology
Prednisone is converted to active prednisolone and modifies inflammation and metabolism.
Mechanism of action and pharmacodynamics
Systemic glucocorticoid activity suppresses inflammatory/immune responses and affects glucose/protein/fat metabolism. Some mineralocorticoid activity contributes to sodium retention, hypertension and potassium loss; suppression of endogenous corticotropin contributes to adrenal suppression.
Pharmacokinetics
- Activation / metabolism
- Prednisone converts to active prednisolone; further metabolism occurs mainly in liver.
- Delayed release
- Approximately 4-hour lag; fed peak ~6–6.5 hours versus ~2 hours for IR in the cited comparison. Fasting decreases delayed-release exposure.
- Elimination
- Prednisolone metabolites are excreted in urine as sulfate/glucuronide conjugates; terminal prednisone/prednisolone half-lives ~2–3 hours in the label comparison.
- Clinical interpretation
- Equivalent total exposure with food does not make administration timing interchangeable.
Monitoring and counseling
Monitor disease response and cumulative steroid toxicity.
Monitoring parameters
- Follow disease response and ongoing need; monitor BP, weight/edema, glucose and potassium during prolonged therapy.
- Assess infection/exposure risk; obtain hepatitis B screening before immunosuppressive treatment and assess relevant latent infection risks.
- Assess bone/fracture risk and preventive treatment; monitor children’s growth. Evaluate vision and check intraocular pressure with prolonged treatment (label threshold >6 weeks).
- Monitor mood/sleep, GI bleeding or perforation symptoms, muscle weakness and signs of adrenal insufficiency during dose changes.
Patient counseling information
- Follow the exact formulation schedule; take with food and swallow delayed-release tablets intact. Do not change a prolonged regimen without review.
- Tell clinicians about current/recent steroid exposure before illness or surgery. If adrenal recovery is unconfirmed, stress coverage may be needed; hemodynamic instability or persistent vomiting requires urgent evaluation and parenteral treatment.
- Report fever/infection exposure, black stools, severe mood changes, visual problems or profound weakness. Discuss vaccines before receiving them.
- Keep an updated medicine list and a clinician-directed plan for tapering and missed doses.
Product identification
Identify strength and release formulation before dosing.
Representative oral product · Prednisone 5 mg
- Dosage form / strength
- Immediate-release tablet · 5 mg
- Labeler
- Par Health USA, LLC
- Appearance / imprint
- White, round, scored · 5094 / V
- Example NDC
- 0603-5337-21 · 100 tablets
Dosage forms and strengths
Selected Par IR tablets: 1, 2.5, 5, 10 and 20 mg. Selected Dr. Reddy’s delayed-release label: 1 and 2 mg unscored tablets. The FDA Rayos brand label describes 1, 2 and 5 mg delayed-release tablets; this historical label does not establish current brand availability. Other tablet/liquid products require their own concentration and handling directions.
Storage and handling
Selected IR tablets: 20–25°C in a tight light-resistant container. Selected delayed-release tablets: 20–25°C, excursions 15–30°C, protected from light/moisture in a tight light-resistant container. Keep out of children’s reach and preserve labeled release formulation identification.
References
Original sources for the clinical and product information.
- DailyMed / National Library of MedicinePrednisone · Par Health immediate-release tablets
Full public manufacturer label and patient instructions; SPL version 36, effective 20260731. Product-specific directions reviewed October 1, 2026.
- DailyMed / National Library of MedicinePrednisone · Dr. Reddy’s delayed-release tablets
Full public manufacturer label and patient instructions; SPL version 5, effective 20260923. Product-specific directions reviewed October 1, 2026.
- U.S. Food and Drug AdministrationRayos · FDA prescribing information
Public FDA label revised March 2024; historical brand reference for 1/2/5 mg delayed-release presentations and directions. Current brand marketing availability not asserted.
- Endocrine Society / European Society of EndocrinologyGlucocorticoid-induced adrenal insufficiency · ESE/Endocrine Society 2024
Official public recommendations dated May 13, 2024; taper and stress coverage recommendations reviewed. Full journal evidence tables not claimed accessed.
- Strides Pharma UK Ltd / electronic medicines compendiumSystemic corticosteroids · Scleroderma renal crisis warning
Primary prednisolone SmPC revised July 29, 2026; section 4.4 systemic-sclerosis class warning. Prednisolone is prednisone’s active metabolite; this is a supplemental UK safety reference, not a U.S. indication source.